Cargando…
Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
Autores principales: | Stegelmann, Frank, Teichmann, Lino L., Heidel, Florian H., Crodel, Carl C., Ernst, Thomas, Kreil, Sebastian, Reiter, Andreas, Otten, Sara, Schauer, Stefanie, Körber, Ruth-Miriam, Kricheldorf, Kim, Isfort, Susanne, Döhner, Hartmut, Brümmendorf, Tim H., Griesshammer, Martin, Döhner, Konstanze, Koschmieder, Steffen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079540/ https://www.ncbi.nlm.nih.gov/pubmed/36828867 http://dx.doi.org/10.1038/s41375-023-01837-9 |
Ejemplares similares
-
Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021) -
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
por: Koschmieder, Steffen, et al.
Publicado: (2022) -
Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2020) -
Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2021) -
Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry
por: Gecht, Judith, et al.
Publicado: (2021)